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Acute myocardial infarction (AMI) is the leading cause of dis-
ability and mortality worldwide.1 The diagnostic and therapeutic
approach to this very frequent and life-threatening disease has con-
siderably evolved during the past decades, perhaps more impres-
sively than any other human disorder.2 This notable evolution has
been paralleled by a constant and timetabled release of diagnostic
guidelines, which have evolved from the celebrated first, through
the second and third,3 up to the recently released fourth Universal
Definition of myocardial infarction.4 Throughout such a relatively
short history (i.e., the first Universal Definition was only published
in 2000),5 the major breakthroughs have concerned the identifica-
tion of cardiac troponins (either I or T) as the reference (and virtu-
ally only) biomarkers of myocardial injury, and the subsequent
development of the so-called high-sensitivity cardiac troponin
immunoassays, which have enabled to increase analytical sensitiv-
ity, precision and reproducibility of these measurements far
beyond the limits of the former techniques. Albeit we may be
indeed persuaded to conclude that cardiac troponins are as yet the
best there is, it may be rather hazardous to put forward the concept
that these biomarkers will be regarded the best there ever will be.
This is simply due to the fact that not all the leading characteristics
of an ideal cardiac biomarker, as shown in Table 1, are thoughtful-
ly met by cardiac troponins.
If on one hand the gradual refinement of both analytical tech-
niques and diagnostic criteria has allowed achieving a faster and
more efficient diagnosis of AMI, the downside of these innova-
tions has been represented by an increasing uncertainty around
both clinical use and result interpretation of high-sensitivity
immunoassays.6 The most disrupting factor is indeed represented
by the possibility to measure physiological cardiac troponin values
in the vast majority (i.e., between 95-99%) of healthy subjects,
which has hence represented an essential paradigm shift in the way
results of cardiac troponin testing have been interpreted for long.
To put it simply, the traditional black & white scenario (i.e., posi-
tive or negative), has turned into a grayscale, according to which
cardiac troponin values exceeding the upper reference limit (URL)
calculated in an ostensibly healthy population are no longer syn-
onyms of myocardial infarction (nor of myocardial injury), and
that measurable concentrations of cardiac troponins above the limit
of detection (or the functional sensitivity) of a high-sensitivity
immunoassay are not as safe as they have for long been consid-
ered. In this puzzling landscape, we believe that there may be – at
least – six major paradigms that should always be considered when
using cardiac troponins for diagnosing myocardial infarction in the
emergency room (Table 2).
First and foremost, cardiac troponins are generic biomarkers of
myocardial injury.4 This concept is not ancillary, wherein many
physicians and laboratory professional are still relying on the
axiom that increased cardiac troponins = AMI. Albeit a thoughtful
description of non-ischemic and non-cardiac causes of cardiac tro-
ponin elevation must be omitted due to space constraints, it may be
worthwhile to mention here that whatever disease either directly
(i.e., myocarditis, myocardial contusion or stunning, high-frequen-
cy atrial fibrillation and so forth) or indirectly (i.e., cancer, pul-
monary embolism, etc.) triggers myocardial injury, this will be
then mirrored by a variable elevation of measurable cardiac tro-
ponin in blood.7 In fact, the Fourth Universal Definition of
Myocardial Infarction underlines, for the first time, the clear-cut
separation between myocardial injury and myocardial infarction,
providing clinical and biochemical criteria for distinction.4
The second important issue concerns the biochemical and bio-
logical heterogeneity of cardiac troponins. Cardiac troponin I and
T are encoded by two different genes, have a completely different
biochemical structure and their metabolism (from intracellular
release to catabolism) is not overlapping.8 As such, the values of
these two biomarkers, although displaying some notably compara-
ble features, are not interchangeable. Quite predictably, therefore,
different immunoassays will generate different results, and this
problem cannot be completely overcome even assaying the same
molecule. More specifically, the currently licensed high-sensitivity
techniques entail one immunoassay for measuring cardiac troponin
T and as many as 4 different immunoassays for measuring cardiac
troponin I. The standardization of these latter methods remains
dramatically poor, since no reference material has been identified
so far, nor standardized epitopes of cardiac troponin I against
which monoclonal antibodies should be produced have been defi-
nitely validated.9 This aspects is of paramount importance for
healthcare facilities operating within a (vast) network, in which
patients may be diagnosed with one cardiac troponin I immunoas-
say in one center, but will then be managed with another method
in another center, e.g., where a cardiac cath lab is available.
The time elapsed between symptoms onset and blood collec-
tion is another major determinant of diagnostic performance.
Regardless of the pathogenesis (AMI currently recognizes at least
5 different underlying pathogenetic mechanisms), irreversible
myocardial necrosis typically occurs 20-40 min after myocardial
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ischemia, and cardiac troponins become measurable only after-
wards.10 This particular pathway is hence mirrored by the kinetics
of cardiac troponins in blood, which is conventionally referred to
as the diagnostic window. Although substantially elevated values
of cardiac troponins may persist in blood for such a long time (i.e.,
between 7 to 10 days, depending on type, size and revasculariza-
tion of the infarct area) that late presentation is not an issue (unlike
myoglobin, for example, whose concentration return to normal
values after 1-3 days after the acute ischemic event), a diagnosis
may be missed in early presenters when blood sampling time is too
narrow. This notion especially concerns the recent publication of
studies entailing the use of so-called short-track protocols, encom-
passing serial sampling at presentation and 30 minutes or 1 hour
afterward. Beside the inherent risk of missing early presenters,
who may hence test negative also at second blood sampling,11 this
approach has many other drawbacks. These typically include the
fact that very fast protocols, especially those entailing second sam-
pling after 30 min from the first blood collection, will carry the risk
that cardiac troponin increases due to an ischemic event may still
be comprised within the biological variability (i.e., the reference
change value) of the biomarker itself, which is approximately 50%
for cardiac troponin I and approximately 20% for cardiac troponin
T, respectively.12 Along this line, Boeddinghaus et al. recently
showed that 0-1 hour algorithms have an optimal diagnostic per-
formance in younger subjects (i.e., 91% of patients aged 40 years
or younger can be safely ruled-out), whilst the proportion of elder-
ly patients (i.e., aged 70 years or older) who could be safely ruled-
out with 0-1 hour blood sampling will dramatically decrease, far
below 40%.13 Even more importantly, the change of cardiac tro-
ponin values which can be appreciated after such a short time may
also be comprised within the analytical imprecision of the
immunoassay, and this will inevitably mislead the clinical interpre-
tation.14 Last but not least, there is an obvious risk that the labora-
tory will receive the second blood sample before the first has been
processed and, likewise, that emergency physicians may also be
confused by receiving two consecutive laboratory reports in such a
short timeframe. Needless to say, the current turnaround time for
cardiac troponin testing has been fixed at 1 hour, so that very fast
protocols would be hardly manageable according to the large vol-
umes and the increasing workflows characterizing modern clinical
laboratories. Taken together, these factors would lead us to con-
clude that using diagnostic algorithms based on second blood sam-
pling after ≥2 hours would be a more precautionary strategy for
both ruling-out and ruling-in AMI.
The diagnostic threshold for considering as to whether a car-
diac troponin value is diagnostic or not of cardiac injury has been
for long based on the 99th percentile URL.3 Several lines of evi-
dence now attest that this strategy carries many drawbacks, whilst
the use of lower cut-offs, perhaps coincident with limit of detection
or functional sensitivity (i.e., the value with ≤10% analytical
imprecision) of the immunoassay may enable earlier and more effi-
cient rule-out.15 Interestingly, values comprised between the URL
and the function sensitivity still retain clinical significance, where-
in the higher the value within this range, the larger the risk of all-
cause mortality. This important evidence has led some authors to
postulate that cardiac troponins may be used as the cholesterol of
the third millennium, despite the fact that management of patients
with measurable (but non-diagnostic) values of cardiac troponins
remains undefined, especially in the short-term period (i.e., within
1-year).16,17
The last and perhaps more debated issue concerns the approach
used for estimating the variation of cardiac troponin between two
consecutive blood samplings. Two current strategies have been
proposed, the former based on absolute variation of cardiac tro-
ponin concentration, and the latter on its percentage variation.
These two approaches have advantages and limitations, so that a
strategy combining both (i.e., the absolute variation when admis-
sion values are below the URL and the percent variation when
admission values are above such threshold) may yield a better
diagnostic performance.14 Whilst theoretically straightforward, this
strategy will need validation in real life scenarios. Interestingly,
recent evidence has also been provided that a combined measure-
ment of both cardiac troponins I and T will increase costs, but does
not seemingly enhance the diagnostic efficiency of algorithms
based on either biomarker alone.18
In conclusion, high-sensitivity cardiac troponin immunoassays
have almost revolutionized the diagnostic approach to patients
with suspected AMI, by increasing the diagnostic performance
(especially in patients with non-ST elevation myocardial infarc-
tion) and providing useful clinical evidence beyond myocardial
ischemia. Nevertheless, some unresolved issues still remain (Table
2), thus paving the way to an advisable update of currently avail-
able recommendations for using results of high-sensitivity
immunoassays in the emergency room.19
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